The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic-industrial partnership 
The background
The Neidle laboratory, which from 1986-2002 was at the Institute of Cancer Research in the UK (ICR), has long been involved in the study of small molecule-nucleic acid interactions, and in the use of X-ray crystallography and molecular modelling for the rational design of sequence-and structure-recognition agents. In the late 1980s he and his colleagues had started on a programme of X-ray analyses of complexes between double-helical oligonucleotides and small molecules that were known to bind in the minor groove of Bform DNA. Many of these compounds were well-established to have biological activity, especially as anti-infective and antiparasitic agents. From 1990 onwards a number of crystal structures of DNA complexes involving for example, the bis-(phenyl amidinium) triazene compound berenil 1,2 , the (Georgia State University, USA), who have pioneered the medicinal chemistry-led discovery and development of lowmolecular-weight minor-groove binding compounds for the treatment of infective diseases. Their work on tropical parasitic diseases such as trypanosomiasis has resulted in one such compound entering advanced clinical trials.
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Earlier crystallographic studies of the dipyrrolic polyamide natural product netropsin by Richard Dickerson and colleagues 8 at UCLA had shown that its binding to AT-rich regions of duplex DNA was in the minor groove. Importantly the convex shape of netropsin complemented the concave surface of the groove, giving rise to the concept of isohelicity 9 to describe the recognition of AT-rich narrow minor groove DNA sequences. Isohelicity suggests that a particular radius of curvature for the ligand is required in order for optimal binding to take place. However combined biophysical and crystallographic studies had shown that this is not necessarily the case since a water molecule can bridge between an amidinium group and a base edge in the groove even if the ligand itself has a linear or near-linear shape.
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The crystal structures being determined in the Neidle laboratory were being used as starting-points in several qualitative and semi-quantitative molecular modelling studies with the initial intent of rationalising patterns of ligand-DNA hydrogen bonding and deciphering the role of water molecules in the recognition process. 11, 12 Around this time, several chemistry-based groups, most prominently that of Peter Dervan at CalTech, were developing chemical ways of recognising increasingly long sequences of duplex DNA, ultimately as gene targeting agents. 13 This approach uses the concept of stringing together simple small building-blocks, (mostly amido-substituted small heterocyclics which could recognise individual bases by hydrogen-bonding to base edges in the minor groove), into larger polyamide molecules, some of which can recognise more than a complete turn of duplex DNA. The approach has subsequently been extremely successful and is now capable of selective recognition of individual genes within a genome such that it is now being studied in animal models as a potential direct therapy for down-regulating the expression of deleterious genes driving a particular disease state (see for example, a description of targeting the estrogen receptor element in cells and in vivo 14 ).
The Neidle group was interested in exploiting its accumulated structural information in an analogous manner, and to using parts of these established minor-groove binding compounds as recognition building-blocks. Typical compounds studied at that time included a number of diamidines such as berenil and pentamidine, the asymmetric bis-benzimidazole DNA stain 16 This led to the families meeting together at a local pizzeria, then inevitably to chemical discussions over drinks, and followed by the resolve to develop a common project together. Crystal structures had provided structural knowledge of the minor groove binding for the well-studied asymmetric bisbenzimidazole compound Hoechst 33258. 4, 17 We decided that since the benzimidazole group was also a well-established pharmacophore with drug-like attributes, it was a suitable scaffold for our joint studies, which were aimed at eventually developing a non-polyamide approach to the recognition of long DNA sequences (perhaps up to 12 base pairs). Molecular modelling used the Hoechst 33258-d(CGCAAATTTGCG) 2 complex crystal structure as a starting-point. The application of simple steric principles (by ensuring that there were no nonbonded close contacts at less than van der Waals separation between the joined-up benzimidazole units and atoms in the DNA minor groove) led to the concept of linking two benzimidazole units in a head-to-head symmetric manner, which was predicted to have the complementary shape needed for effective AT base recognition. The modelling indicated that this would be distinct from Hoechst 33258, Scheme 1 would recognise four contiguous AT base pairs, and chemical functionality would be achieved via para substitution on a phenyl ring directly attached to each benzimidazole group. After the summer break, the Mann group embarked on the synthesis of the new series of bis-benzimidazoles (termed BBZs) suggested by the modelling, which had not been previously reported in the literature, and this research continued uninterrupted until 2008, firstly at the University of Reading and later at Queen's University Belfast. The initial series of compounds were prepared 18 by a very able Ghanaan
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PhD student, Yaw Oboku-Boahen, through the oxidative condensation between 3,3',4,4'-tetraaminobiphenyl and various simple 4-substituted aromatic aldehydes (eg 4-methoxy and 4-hydroxy). This reaction (Scheme 1) required heating the compounds in nitrobenzene at 150 °C for 8-10 hours and although the required bis-benzimidazoles were obtained the yields were 25-40% at best. Although the yields were improved by a French PhD student, Anne Baron, thus allowing initial biological evaluation to be carried out, a new milder method was required to provide greater quantities of products. This was discovered and optimised by two excellent postdoctoral fellows, Xiao-Wen Sun and Christine Le Sann. 19, 21 This involved treating the tetraamine and aryl aldehydes in DMF with the oxidant Oxone at room temperature and typical reaction times of 18 hours. With this reaction method even complex bis-benzimidazoles such as a chlorambucil mustard derivative could be prepared in yields of up to 80%.
Once a number of substituted BBZs became available, a technical officer (Emma Rayner), and two PhD students (Ian Simpson and Eric Johansson) in the Neidle group undertook crystallographic studies of the bis-(3"-hydroxy) and bis-(3"-dimethylamino-1"-propyloxy) derivatives (Figure 1 ), bound to dodecanucleotide DNA duplexes (Protein Data Bank ids 453D and 1FTD).
18,20 The prediction of four base-pair recognition was verified by these crystallographic studies as well as by DNA foot-printing studies conducted by Keith Fox (University of Southampton). Studies by the late Lloyd Kelland (ICR) and John Hartley (University College London) showed that several compounds in the series showed sub-µM inhibition of cell growth in a panel of ovarian cancer cell lines, with the bis-(3"-dimethylamino-1"-propyloxy) derivative being the most active whereas substituents with uncharged and more hydrophobic end-groups resulted in a loss of activity. 20, 21 The bis-(3"-dimethylamino-1"-propyloxy) derivative showed some modest anti-tumour activity in human cancer xenograft models 20 , although this was insufficient to convince external funders. (representatives of two major MRSA clones isolated from U.K. hospitals) and Group A and Group B streptococci. The minimum drug concentrations required to prevent overnight bacterial growth (MIC) against these Gram-positive bacteria were impressive, ranging from 0.03 -I µg/ml, and there was no evidence of cross-resistance with any other group of antibacterial agents -strongly suggestive of a novel mechanism of antibacterial action.
This promising data led to two successful grant applications that provided an opportunity to assess the antibacterial potential of a wider collection of BBZs. In 2007, an Academic Excellence Award from the Royal Pharmaceutical Society, achieved through national competition, enabled an investigation of the potency and antibacterial spectrum of activity of these compounds. A Capacity Building Award from the Medical Research Council facilitated insights into the mode of action of these putative drugs. A graduate student on the Royal Pharmaceutical Society award, Joao Moreira, profiled 21 symmetric and asymmetric BBZs against a comprehensive panel of Gram-positive clinical isolates, including ten from the initial series synthesised by John Mann and co-workers. This in-depth study 23 confirmed the lack of activity against a wide range of Gram-negative pathogens but established that three compounds in particular possessed potent anti-staphylococcal activity against four methicillin-susceptible S. aureus and 61 Of particular interest was the relatively strong and previously unreported activity of several BBZs against Mycobacterium tuberculosis (Mtb); this was manifest against both the standard laboratory Mtb strain H37RV and 10:104, a recently isolated drug-hetero-resistant Mtb bacterium. Further, the compounds were active against logarithmic phase cultures and latent cultures induced by hypoxia. This latter activity, together with the fact that they were active against resistant clinical isolates, suggested that they represent promising lead compounds for development of an anti-Mtb agent active against latent forms of the pathogen through a novel mechanism of action. Treatment of latent tuberculosis is a vital component of elimination of the disease but is not efficiently implemented with currently available drugs. Summit entered the picture John Mann's initial interactions with Summit Therapeutics (www.summitplc.com) in 2007 resulted in an initial small-scale project in which they independently agreed to evaluate the MRSA activity of a set of BBZ compounds. This took place soon after the first set of data became available from Peter Taylor's laboratory, and involved outsourcing the screening work to a contract research organisation (CRO), with Richard Vickers leading the Summit activity. This new data set fully confirmed the findings from the Taylor laboratory and at this point all involved decided to work closely together and jointly develop a strategy for the future development of the BBZ compounds. A major early issue was the commercial potential of the MRSA activity. A patent granted in 1998 to Roche in Basle with inventors Walter Häsler, Werner Leupin and Yu-Hau Ji 25 had come to light, which covered antibacterial activity for a number of uncharged BBZs. Although the patent focussed on E. coli, a few S. aureus strains were mentioned. Summit undertook some medicinal chemistry in order to attempt to improve on the existing activity and move into novel chemical space. However it soon became apparent that it would be more fruitful to focus on alternative bacterial targets, and Summit suggested in particular working on Clostridium difficile infections. C. difficile is a serious hospital-associated bacterial disease which especially affects the elderly and is hard to treat with existing drugs. In 2011 it was responsible for over 2,000 deaths in the UK, and is estimated to cause over 30,000 deaths in the USA. As the School of Pharmacy was not initially set up to work on this pathogen, Summit commissioned C. difficile compound evaluation at several CROs. Again potent activity was observed in several of the uncharged initial BBZ compounds. Summit then embarked on a comprehensive medicinal chemistry programme to optimise activity with appropriate physicochemical properties. The medicinal chemistry effort found that the structureactivity requirements were exceptionally narrow and that significant deviations from the original BBZ concept were not tolerated in that the overall curvature and shape of the BBZ scaffold are absolute requirements for retention of activity. This work culminated in the discovery of the novel antibiotic SMT19969 26 , which is very closely related to the original BBZ compounds invented by Stephen Neidle and John Mann, and represents a fundamental repositioning of particular BBZ compounds from generalised cell proliferation inhibitors to targeted anti-infective agents. A subsequent Wellcome Trust Seeding Drug Discovery funded project funded some further chemistry, together with extensive animal and pre-clinical toxicology work on the lead compound, with its biological properties being characterized in collaboration with the Neidle laboratory. Table 1 summarises anti-bacterial data for three representatives of the early BBZ compounds, together with data on SMT19969. In terms of mechanism of action, although this has not yet been definitively determined for SMT19969, it is clear from the gyrase and other data that it differs from the other BBZs and is for example not a gyrase or topoisomerase inhibitor in C. difficile, nor does it bind to duplex DNA. SMT19969 does not obey 4/5 of Lipinski's rules, which is precisely why it looks to be such an effective drug for C. difficile infections: as a consequence it is not orally bioavailable and is retained in the gut, in close physical proximity to C difficile bacteria.
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Summit Therapeutics has subsequently undertaken the further development of the series leading to the advancement of SMT19969 into current clinical trials in humans. This compound shows exceptional selectivity and potency for the bacterium 27-29 and pre-clinical data indicated that it has remarkably low toxicity, which was confirmed by a Phase I One could argue that the discovery of SMT19969 was accidental, with the key events being the evaluation of the existing BBZ compounds for anti-bacterial activity. However such "accidents" do not occur randomly -they require that those involved are smart enough to spot something of interest, worthy of an investment in time and money. Similarly the initial invention of the BBZ series by John Mann and Stephen Neidle, even though it was initiated by a chance meeting, was based on a great deal of prior knowledge of the structural features of minor groove-binding agents. The BBZ compounds came about, not because Mann and Neidle saw the project as an opportunity to write a grant proposal, but simply because they were enthused by the science and its possibilities, and that they wished to work together on a project of mutual interest. The fact that the original intent of creating novel DNA recognition units based on the BBZ scaffold has been superseded by a quite distinct goal, of creating novel anti-infective agents, is to our minds, a powerful argument for fostering basic science and ensuring that opportunistic links are put in place to assess the therapeutic potential of any outcomes.
All of this would not have come to a focus, and SMT19969 would not have existed without the involvement of a commercial organisation, nimble enough to spot a potential opportunity. Whether a larger organisation would have become involved so quickly, or at all, is an interesting question (the original patent assigned to Roche, was abandoned by them before SMT19969 existed). Any early-stage therapeutic project requires substantial funding in order to progress and the Wellcome Trust's enthusiastic support via its Seeding Drug Discovery Programme was crucial. It is notable that this support was not based on the normal requirement of a validated target (as stated above the target(s) are still unclear), but on a robust case focussed around unmet clinical need and the properties of SMT19969 to effectively meet this need. 
